2022
DOI: 10.1016/j.ijbiomac.2022.02.057
|View full text |Cite
|
Sign up to set email alerts
|

Fabrication of astaxanthin-enriched colon-targeted alginate microspheres and its beneficial effect on dextran sulfate sodium-induced ulcerative colitis in mice

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
12
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 28 publications
(12 citation statements)
references
References 53 publications
0
12
0
Order By: Relevance
“…Additionally, Ax-Alg has been shown to increase IL-10 levels while reducing IL-6 and IL-1β levels (Fig. 15 ) [ 113 ].
Fig.
…”
Section: Nanomedicine For the Treatment Of Ibdmentioning
confidence: 99%
“…Additionally, Ax-Alg has been shown to increase IL-10 levels while reducing IL-6 and IL-1β levels (Fig. 15 ) [ 113 ].
Fig.
…”
Section: Nanomedicine For the Treatment Of Ibdmentioning
confidence: 99%
“…Alginate microspheres were fabricated to deliver astaxanthin, an excellent antioxidant, to the colon, and in vitro models showed that the microspheres could tolerate well the conditions in the mouth, stomach and small intestine, and reach the colon where astaxanthin was released due to the fermentation of gut microbiota. 31 Although specifically degraded in the colon, many polysaccharides are hydrophilic and swell under exposure to the upper GIT, leading to premature drug release. Thus, researchers usually use a combination of polysaccharides to overcome this shortcoming.…”
Section: The Rationale For Designing An Oral Colon-specific Delivery ...mentioning
confidence: 99%
“…As the applications of AST are limited by its poor water-solubility and loss of bioactivity during the digestion process, some studies utilized an encapsulation system to improve the bioavailability of AST. Zhang et al prepared an AST-enriched colon-targeted alginate particle (AST-Alg) and tested its efficacy in mice with DSS-induced ulcerative colitis [ 145 ]. Compared to the DSS-treated control group, mice that received AST-Alg (30 ppm of AST; nine weeks) showed lower levels of inflammation, oxidative damage, colonic mucosal integrity, and body weight loss.…”
Section: Ulcerative Colitismentioning
confidence: 99%